膀胱尿路上皮癌MRP-1/CD9和cyclinD1的表达与肿瘤生物学行为的关系

Ralativity of MRP-1/CD9 and cyclinD1 expression in bladder urothelial carcinoma and tumor biological behavior

目的:探讨MRP-1/CD9和cyclinD1的表达与膀胱尿路上皮癌生物学行为的关系。方法:应用免疫组化法检测80例膀胱尿路上皮癌组织和12例正常对照组膀胱组织MRP-1/CD9和cyclinD1的表达情况。结果:MRP-1/CD9阳性表达率膀胱癌组为51.25%,对照组为91.11%(P<0.05);Ta～T1肿瘤阳性表达率为71.42%,T2～T4为35.56%;G1肿瘤阳性表达率为78.57%,G2为43.48%,G3为31.03%,随着肿瘤浸润性和分级上升,阳性表达率逐渐下降(P<0.01,P<0.05);MRP-1/CD9阳性表达率肿瘤初发和复发者之间差异无统计学意义(P>0.05);肿瘤单发者高于多发者(P<0.05)。膀胱尿路上皮癌cyclinD1阳性表达率为53.75%,对照组为0(P<0.01);Ta～T1肿瘤阳性表达率为78.57%,T2～T4为17.65%;G1肿瘤阳性表达率为85.71%,G2为56.52%,G3为20.69%,随着肿瘤浸润性和分级升高,cyclinD1阳性表达率逐渐降低(P<0.05,P<0.05)。cyclinD1阳性表达率肿瘤初发和复发者、多发者和单发者之间差异无统计学意义(P>0.05,P>0.05)。结论:MRP-1/CD9表达与膀胱尿路上皮癌的浸润性和分级相关,其表达缺失可能是判断该肿瘤预后的一个指标;cy-clinD1较能准确地评估膀胱尿路上皮癌的生物学行为。

Objective：This study was to explore the expression and significance of cyclinD1 and MRP-1/CD9 in bladder urothelial carcinoma. Methods： MRP-1/CD9and cyclinD1 expression of 80 cases of bladder urothelial carci- noma and 12 normal control bladder tissue was detected by immunohistochemical technique. Results： The positive expression rate of MRP-1/CD9 in bladder cancer bladder was 51.25% in the control group 91.11% （P〈0.05）. Ta-T1 tumors positive rate was 71.42%, T2-T4 was 35.56%. G1 tumors positive expression rate was 78.57%, G2 was 43. 480/oo, G3 was 31. 03%. with increased tumor invasive and grade, the positive expression rate decreased （P〈0.01, P〈0.05）. MRP-1/CD9 positive expression rate of tumor onset and recurrence was no significant difference（P〉0.05）, and multiple lesions were greater than singular lesions（P〈0.05）. Bladder urothelial carci- noma cyelinD1 positive expression rate of 53.75% in the control group 0 （P〈 0.01）. Ta-T1 tumors positive rate was 78. 57%, T2-T4 was 17. 65%, G1 tumors positive expression rate was 85. 71%, G2 was 56.52%, G3 was 20.69%. With the increase in tumor invasive and grade, cyclinD1 positive rate decreased（P〈0.01, P〈0.05）. eyclinD1 positive rate of tumor onset and recurrence of tumor, multiple and single were no statistically significant difference（P〉0.05, P〉0.05）. Conclusions： In patients with urothelial bladder carcinoma, MRP-1/CD9 expres- sion was associated significantly with tumor invasive and grade, and a loss of MRP-1/CD9 expression was an prog- nostic factor for predicting progression in patients with urothelial bladder carcinoma, cyclinD1 may be a more accu- rate assessment of bladder urothelial carcinoma of the biological behavior. The detection of the expression of MRP- 1/CD9 and cyclinD1 is in favor of diagnosis and prognostic evaluation of bladder cancer.